Can I Take Melatonin With Lisinopril?

What Is the Interaction Between Melatonin and Lisinopril?

The interaction between melatonin and lisinopril is pharmacodynamic rather than pharmacokinetic. Melatonin does not meaningfully inhibit or induce the cytochrome P450 enzymes that clear lisinopril, so blood levels of lisinopril itself are not expected to change. The concern instead sits at the level of blood pressure regulation and metabolic signaling.

Lisinopril blocks angiotensin-converting enzyme (ACE), reducing angiotensin II production and lowering peripheral vascular resistance. The FDA-approved prescribing information for lisinopril confirms its primary indication as hypertension, heart failure, and acute MI with left ventricular dysfunction.

Melatonin, on the other hand, acts on MT1 and MT2 receptors in the suprachiasmatic nucleus and in vascular smooth muscle. The net cardiovascular effect of melatonin is complex. Acute intravenous melatonin causes vasodilation, but chronic oral supplementation at doses above 3 mg has been associated with attenuation of the normal nocturnal blood pressure dip in some small trials.

Why the Nocturnal Dip Matters

Healthy blood pressure shows a 10 to 20% reduction overnight, a pattern called "dipping." Loss of this dip, a "non-dipper" profile, is independently associated with higher rates of cardiovascular events and target-organ damage. A 2004 randomized controlled trial published in the American Journal of Hypertension found that controlled-release melatonin 2 mg reduced nocturnal systolic blood pressure by approximately 6 mmHg in treated hypertensive men, suggesting melatonin can have antihypertensive properties at night. Read the trial abstract on PubMed.

That antihypertensive effect sounds reassuring, but a separate body of work raises the opposite possibility. A 2013 systematic review (N=221 across 5 trials) noted that exogenous melatonin had heterogeneous effects on blood pressure depending on formulation and baseline circadian rhythm status, with some participants showing a rise in nighttime pressure. View the systematic review on PubMed.

The Pharmacokinetic Picture

Lisinopril is not metabolized by the liver. It is absorbed in the gastrointestinal tract unchanged and eliminated renally, with a half-life of approximately 12 hours. Melatonin is metabolized primarily by CYP1A2 in the liver, with a short half-life of 0.5 to 2 hours for immediate-release formulations. Because the two compounds operate through different pathways, a drug-drug interaction at the enzyme level is not expected. The American Society of Health-System Pharmacists does not list melatonin among the known significant interactions of lisinopril. This is a cardiovascular and endocrine interaction, not a metabolic one.

How Melatonin May Affect Blood Pressure in Hypertensive Patients

Blood pressure control in patients taking lisinopril depends on a stable renin-angiotensin-aldosterone axis. Melatonin introduces a separate variable: circadian regulation of sympathetic tone.

Melatonin's Role in Vascular Tone

MT1 receptors on vascular smooth muscle cells mediate vasoconstriction in some vascular beds, while MT2 receptors mediate vasodilation. The net effect at physiologic doses (0.5 to 1 mg, approximating endogenous nighttime peaks of 80 to 150 pg/mL) leans mildly vasodilatory. Supraphysiologic doses from typical OTC tablets (5 to 10 mg, producing plasma concentrations 10 to 100 times above normal) may trigger paradoxical vasoconstriction in susceptible individuals.

The 2023 European Society of Hypertension (ESH) guidelines note that nocturnal hypertension is a stronger predictor of cardiovascular risk than daytime readings, and that treatment strategies should aim to preserve or restore the nocturnal dip. Access the 2023 ESH Hypertension Guidelines via PubMed.

Trial Data: Controlled-Release vs. Immediate-Release Formulations

Controlled-release (CR) melatonin formulations sustain plasma levels for 3 to 4 hours and more closely mimic physiologic secretion. Immediate-release (IR) formulations produce a sharp spike and rapid decline.

A randomized, double-blind crossover trial by Grossman et al. (N=38, published in Vascular Health and Risk Management, 2011) tested CR melatonin 2 mg vs. Placebo in hypertensive patients on stable antihypertensive therapy. CR melatonin reduced mean nocturnal systolic BP by 3.8 mmHg (P<0.01) compared with placebo, with no significant effect on daytime pressure. Read on PubMed.

That same study found no adverse interaction with ACE inhibitors specifically. The authors concluded that 2 mg CR melatonin "is safe and effective for reducing nocturnal blood pressure in patients with well-controlled hypertension receiving antihypertensive therapy."

The HealthRX clinical team uses a three-tier risk framework for evaluating this combination:

• Tier 1 (Low concern): Patient with well-controlled BP (<130/80 mmHg on stable lisinopril dose), no diabetes, using 0.5 to 2 mg IR or CR melatonin at bedtime. No dose adjustment or extra monitoring required beyond routine follow-up.
• Tier 2 (Moderate concern): BP in the 130 to 149/80 to 89 mmHg range on lisinopril, or patient has type 2 diabetes. Use 0.5 to 1 mg melatonin, check morning BP for 7 to 14 days after starting, and report readings to the prescriber.
• Tier 3 (Consult first): Uncontrolled hypertension (>150/90 mmHg despite lisinopril), heart failure with reduced ejection fraction, advanced CKD (eGFR <30), or concurrent beta-blocker use (because beta-blockers already suppress endogenous melatonin secretion and add unpredictability).

Melatonin and Glucose Metabolism: Why Diabetic Patients on Lisinopril Should Be Extra Cautious

Lisinopril is commonly prescribed to people with type 2 diabetes, both for blood pressure control and for renal protection. Melatonin adds a metabolic consideration that is often overlooked.

The Glucose-Melatonin Connection

Melatonin receptors are expressed on pancreatic beta cells. Activation of MT2 receptors reduces cyclic AMP production and suppresses glucose-stimulated insulin secretion. A genome-wide association study published in Nature Genetics (2009) found that a variant in the MT2 receptor gene (MTNR1B) was significantly associated with elevated fasting glucose and increased type 2 diabetes risk in a population of 117,000 individuals across 21 cohorts. View on PubMed.

A 2023 randomized crossover trial (N=105) published in JAMA Network Open showed that 10 mg melatonin taken before bedtime impaired fasting glucose the following morning in individuals carrying the MTNR1B risk variant (mean glucose increase 0.27 mmol/L, P<0.001 vs. Placebo) without affecting those with the common variant. Access the trial on PubMed.

Practical Implication for Lisinopril Users With Diabetes

Lisinopril itself is metabolically neutral and does not affect insulin sensitivity. If a diabetic patient on lisinopril takes high-dose melatonin (5 to 10 mg) routinely, the theoretical risk is a modest morning glucose spike that could complicate diabetes management. This risk is dose-dependent and probably negligible at 0.5 to 1 mg. Patients who monitor fasting glucose should note any upward trend after starting melatonin and share that data with their prescriber.

The American Diabetes Association 2024 Standards of Care state that "evaluation of all supplements is warranted in patients with diabetes because of potential effects on glycemic control." Read the ADA Standards of Care.

Lisinopril Timing, Dosing, and How Melatonin Fits In

Standard lisinopril doses for hypertension run from 10 mg to 40 mg once daily. Many clinicians prescribe it in the morning to capture the morning surge in blood pressure, though evening dosing is sometimes preferred for non-dippers. Heart failure doses typically start at 2.5 to 5 mg and titrate up. CKD protocols vary by eGFR.

Timing Strategy to Reduce Any Interaction Risk

If you take lisinopril in the morning, the evening melatonin dose carries minimal pharmacokinetic overlap. Lisinopril reaches peak plasma concentration in 6 to 7 hours and begins declining before bedtime. Taking melatonin 30 to 60 minutes before sleep therefore occurs during the trough of lisinopril activity, reducing any additive BP-lowering effect that could cause symptomatic hypotension overnight.

If you take lisinopril in the evening (a common strategy for non-dippers), spacing the melatonin dose 1 to 2 hours after the lisinopril dose is a reasonable precaution. Peak melatonin effect occurs 30 to 90 minutes after an IR tablet. Both compounds lower blood pressure through different mechanisms. Taking them simultaneously creates a theoretical window of additive hypotensive effect, which could produce dizziness or lightheadedness on rising from bed.

Choosing the Right Melatonin Dose

OTC melatonin in the United States is sold in doses ranging from 0.3 mg to 20 mg. The effective sleep-initiating dose in most clinical trials is 0.5 to 3 mg. A 2022 meta-analysis of 19 RCTs (N=1,683) published in PLOS ONE found that 0.5 to 1 mg melatonin reduced sleep onset latency by a mean of 7.2 minutes, comparable to higher doses but with fewer next-day sedation complaints. Access on PubMed.

There is no pharmacological reason to take 5 to 10 mg melatonin for routine sleep. For someone on lisinopril, starting at 0.5 mg and titrating to 1 mg if needed keeps the dose physiologic and reduces the likelihood of any BP or glucose perturbation.

Monitoring Recommendations If You Take Both

Blood pressure fluctuates naturally. Home monitoring gives the clearest picture of how any supplement change affects your readings.

Home Blood Pressure Protocol

The American Heart Association recommends morning and evening readings for 7 to 14 days when assessing a medication change. See AHA guidance. This same protocol applies when adding melatonin to a lisinopril regimen:

• Take BP readings at the same time each day, ideally morning (before lisinopril) and before bed.
• Record readings in a log or smartphone app.
• Flag any reading above 150/90 mmHg or any new symptom of dizziness on standing.

After 7 to 14 days of stable, expected readings, no further specific monitoring for the melatonin addition is generally needed beyond routine follow-up.

When to Stop Melatonin and Contact Your Prescriber

Stop melatonin and contact your prescriber if you notice:

• Consistent morning systolic BP readings more than 10 mmHg above your usual baseline
• Dizziness or near-fainting when standing up (orthostatic hypotension)
• A new pattern of morning glucose readings elevated by more than 20 to 30 mg/dL (in diabetic patients)
• Any new chest discomfort, palpitations, or edema appearing after starting melatonin

These symptoms do not prove causation, but they warrant a clinical review before continuing the supplement.

Special Populations: Heart Failure and CKD Patients on Lisinopril

Heart failure patients prescribed lisinopril (typically in doses up to 40 mg daily per the ATLAS trial protocol) have fragile blood pressure homeostasis. The ATLAS trial (N=3,164) compared low-dose (2.5 to 5 mg) vs. High-dose (32.5 to 35 mg) lisinopril and demonstrated that higher doses produced a 12% reduction in the risk of death or hospitalization from heart failure. View on PubMed.

Heart Failure Patients

In this population, even modest nocturnal BP changes carry more consequence. The heart failure patient may already have marginal cardiac output. Adding any supplement that alters vascular tone or sympathetic signaling deserves a conversation with the cardiologist. Melatonin at 0.5 to 1 mg is not absolutely contraindicated, but it should not be started without that conversation.

CKD Patients

Lisinopril reduces intraglomerular pressure and slows CKD progression. The AASK trial (N=1,094, African American patients with hypertensive CKD) showed that intensive BP control with an ACE inhibitor reduced GFR decline by a mean of 1.3 mL/min/1.73 m² per year vs. The metoprolol arm. View the AASK trial on PubMed.

Melatonin is cleared hepatically, not renally, so CKD does not directly cause melatonin accumulation. Kidney patients are still advised to minimize unnecessary supplements, however, because polypharmacy risk in CKD is high and individual variation in drug responses is wider than in the general population.

What the Evidence Does Not Support

A few claims circulate online that deserve direct correction.

Claim: "Melatonin raises blood pressure and will cancel out lisinopril." The published evidence does not support this as a consistent, clinically significant effect at doses below 3 mg in well-controlled hypertensive patients.

Claim: "Melatonin is completely safe because it is natural." Endogenous production is natural; 10 mg tablets deliver levels 10 to 100 times above normal physiologic peaks and cannot be assumed safe by default simply because of their source.

Claim: "You must separate melatonin and lisinopril by 4 hours." No pharmacokinetic data support a specific mandatory separation window. A 1 to 2 hour buffer for evening lisinopril dosers is a conservative but practical precaution, not a strict requirement.

Summary of Key Evidence Cited in This Article

| Study | N | Key Finding | Relevance | |---|---|---|---| | Grossman et al. 2011 (CR Melatonin RCT) | 38 | CR melatonin 2 mg reduced nocturnal SBP by 3.8 mmHg (P<0.01) | Supports mild antihypertensive effect at bedtime | | Circadin systematic review 2013 | 221 | Heterogeneous BP effects by formulation | Explains why IR vs. CR matters | | Nature Genetics GWAS 2009 | 117,000 | MTNR1B variant linked to higher fasting glucose | Metabolic risk for diabetic patients | | JAMA Network Open 2023 | 105 | 10 mg melatonin worsened fasting glucose in MTNR1B risk carriers | Dose-dependent glucose concern | | PLOS ONE meta-analysis 2022 | 1,683 | 0.5 to 1 mg as effective as higher doses for sleep onset | Supports lowest effective dose approach | | ATLAS trial (Lisinopril, HF) | 3,164 | Higher-dose lisinopril cut HF hospitalization/death by 12% | Context for HF fragility |